Start Date
March 1, 2023
Primary Completion Date
April 20, 2024
Study Completion Date
January 11, 2025
INCAGN01876
INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.
retifanlimab
retifanlimab will be administered via IV Q4W
Mount Sinai Prime, New York
University of Maryland-Greenebaum Cancer Center, Baltimore
The Adult Outpatient Pavilion At Vcu, Richmond
Uab Medicine-the Kirklin Clinic, Birmingham
Norton Cancer Institute, Louisville
University of Cincinnati Cancer Institute, Cincinnati
Karmanos Cancer Institute, Detroit
University of Chicago, Chicago
University of Kansas Cancer Center, Westwood
Md Anderson Cancer Center, Houston
University of Utah, Salt Lake City
Toi Clinical Research, Whittier
University of California San Diego Medical Center, Moores Cancer Center, La Jolla
Stanford University, Palo Alto
Providence Portland Med. Ctr, Portland
Dana Farber Cancer Institute, Boston
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
Lead Sponsor
Incyte Biosciences International Sàrl
INDUSTRY